China NMPA Product Recall - Medical magnetic resonance imaging system

Philips Medical Systems Nederland B.V. has initiated a voluntary Class II recall concerning its medical magnetic resonance imaging (MRI) systems. This important action, publicly reported by Philips (China) Investment Co., Ltd. and published by the National Medical Products Administration (NMPA) on May 24, 2024 (Index No. JGXX-2024-10086), stems from a critical software problem identified within the system. The recall specifically impacts MRI equipment manufactured by Philips Medical Systems Nederland B.V. under National Medical Device Registration Certificate No. 20153062757.

The primary issue necessitating this recall is a software malfunction, which could potentially affect the safety or performance of the medical devices. While specific inspection dates were not provided in the document, the recall was publicly announced on the aforementioned date. The regulatory framework under which this recall is managed is overseen by the NMPA, ensuring adherence to national medical device safety standards. As a Class II recall, it signifies that the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

Required actions involve the comprehensive recall of affected units, with detailed information on specific models, specifications, and batches made available in the 'Medical Device Recall Event Report Form.' This proactive measure by Philips underscores its commitment to patient safety and product integrity, addressing the root cause through a structured recall process to mitigate potential risks associated with the software deficiency.